Menu
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Clinical Trial
Investor Centre
Welcome
Investor Fact Sheet
ASX Announcements
Reports
Annual Reports
Half Yearly Reports
Quarterly Reports
Top 20 Shareholders
Research Reports
Shareholder Services
Investor FAQs
US Shareholders
Investor Newsletters
Communication
In the News
Presentations
Contact Us
Contact Us
Email Alerts
In the news
Recent Posts
Interim Data from ACCENT Pancreatic Cancer Trial
Dr Chris Burns elected as a Fellow to the Australian Academy of Health and Medical Sciences (AAHMS)
ASX Briefs podcast | Interview with Dr Chris Burns
Recruitment Restarts in Accent Pancreatic Cancer Trial
NBN News Interview
Dr Chris Burns Announced as Co-Recipient of 2024 Prime Minister's Prize for Innovation
Categories
Archive
Company News
Investor Newsletters
Videos
16 Apr 2024
Entitlement Offer to raise $4.27m
Read More
13 Feb 2024
Proactive Interview with Dr Chris Burns
Read More
18 Jan 2024
FDA clearance of Amplia's IND for pancreatic cancer trial in US
Read More
17 Jan 2024
First patient dosed in phase 2a ACCENT trial
Read More
18 Dec 2023
Investor Newsletter - December 2023
Read More
04 Dec 2023
Approval from Korean regulator to initiate Phase 2 accent pancreatic cancer trial in Korea
Read More
21 Nov 2023
AUSBIZ | Interview with Dr Chris Burns
Read More
30 Oct 2023
Phase 1B of ACCENT Trial in Pancreatic Cancer Complete
Read More
20 Oct 2023
VIDEO | The Market Herald
Read More
09 Oct 2023
AACR Ovarian Cancer Conference Presentation
Read More
29 Sep 2023
Poster presentation at AACR Special Conference on Pancreatic Cancer
Read More
25 Sep 2023
Amplia appoints new CFO
Read More
02 Aug 2023
ACCENT Trial Recruitment Update
Read More
31 Jul 2023
Quarterly Activities and Cash Flow Report - 30 June 2023
Read More
20 Jul 2023
Investor Newsletter July 2023
Read More
19 Jul 2023
Dr Chris Burns to speak at Bio Connections Australia
Read More
21 Jun 2023
International Nonproprietary Name announced for AMP945
Read More
13 Jun 2023
Independent Non-Executive Director recognised in King’s Birthday Honours List
Read More
29 May 2023
AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer
Read More
22 May 2023
PROACTIVE INTERVIEW | Dr Chris Burns discusses Amplia's collaboration with CSIRO
Read More
1
2
3
4
5
6
